TAKE Solutions Limited (TAKE.NS)
INR 8.42
(1.94%)
INR 8.42
(1.94%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 656.08 Million INR | -65.3% |
| 2022 | 1.89 Billion INR | -71.14% |
| 2021 | 6.55 Billion INR | -15.35% |
| 2020 | 7.74 Billion INR | -65.02% |
| 2019 | 22.12 Billion INR | 8.53% |
| 2018 | 20.38 Billion INR | 28.46% |
| 2017 | 15.87 Billion INR | 18.05% |
| 2016 | 13.44 Billion INR | 30.52% |
| 2015 | 10.3 Billion INR | 41.03% |
| 2014 | 7.3 Billion INR | -10.44% |
| 2013 | 8.15 Billion INR | -1.98% |
| 2012 | 8.31 Billion INR | 18.23% |
| 2011 | 7.03 Billion INR | 40.65% |
| 2010 | 5 Billion INR | 42.22% |
| 2009 | 3.51 Billion INR | 4.87% |
| 2008 | 3.35 Billion INR | 14.13% |
| 2007 | 2.93 Billion INR | 61.34% |
| 2006 | 1.82 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 Q3 | 168.51 Million INR | -6.86% |
| 2023 Q4 | 132.06 Million INR | -21.63% |
| 2023 FY | 656.08 Million INR | -65.3% |
| 2023 Q1 | 174.58 Million INR | -46.57% |
| 2023 Q2 | 180.93 Million INR | 3.64% |
| 2022 Q4 | 326.71 Million INR | -39.05% |
| 2022 FY | 1.89 Billion INR | -71.14% |
| 2022 Q2 | 448.84 Million INR | -22.49% |
| 2022 Q3 | 536.03 Million INR | 19.42% |
| 2022 Q1 | 579.1 Million INR | 40.49% |
| 2021 Q3 | 2.07 Billion INR | 5.05% |
| 2021 Q4 | 412.19 Million INR | -80.13% |
| 2021 FY | 6.55 Billion INR | -15.35% |
| 2021 Q2 | 1.97 Billion INR | -5.61% |
| 2021 Q1 | 2.09 Billion INR | -5.36% |
| 2020 Q2 | 1.7 Billion INR | 2.92% |
| 2020 Q3 | 2.16 Billion INR | 26.74% |
| 2020 Q4 | 2.2 Billion INR | 2.13% |
| 2020 FY | 7.74 Billion INR | -65.02% |
| 2020 Q1 | 1.65 Billion INR | -55.24% |
| 2019 Q4 | 3.7 Billion INR | -43.07% |
| 2019 Q2 | 6.08 Billion INR | 4.4% |
| 2019 Q1 | 5.82 Billion INR | 9.14% |
| 2019 FY | 22.12 Billion INR | 8.53% |
| 2019 Q3 | 6.51 Billion INR | 7.02% |
| 2018 Q1 | 4.67 Billion INR | 3.0% |
| 2018 Q3 | 5.21 Billion INR | 1.12% |
| 2018 Q4 | 5.33 Billion INR | 2.36% |
| 2018 FY | 20.38 Billion INR | 28.46% |
| 2018 Q2 | 5.15 Billion INR | 10.34% |
| 2017 Q4 | 4.53 Billion INR | 11.25% |
| 2017 FY | 15.87 Billion INR | 18.05% |
| 2017 Q3 | 4.08 Billion INR | 10.0% |
| 2017 Q2 | 3.7 Billion INR | 4.67% |
| 2017 Q1 | 3.54 Billion INR | -0.32% |
| 2016 FY | 13.44 Billion INR | 30.52% |
| 2016 Q1 | 3.17 Billion INR | 1.79% |
| 2016 Q2 | 3.28 Billion INR | 3.37% |
| 2016 Q3 | 3.43 Billion INR | 4.48% |
| 2016 Q4 | 3.55 Billion INR | 3.63% |
| 2015 Q4 | 3.12 Billion INR | 25.94% |
| 2015 FY | 10.3 Billion INR | 41.03% |
| 2015 Q3 | 2.47 Billion INR | 2.52% |
| 2015 Q2 | 2.41 Billion INR | 5.74% |
| 2015 Q1 | 2.28 Billion INR | 6.25% |
| 2014 Q2 | 1.69 Billion INR | 4.64% |
| 2014 Q1 | 1.61 Billion INR | -17.86% |
| 2014 FY | 7.3 Billion INR | -10.44% |
| 2014 Q4 | 2.15 Billion INR | 16.47% |
| 2014 Q3 | 1.84 Billion INR | 9.26% |
| 2013 Q1 | 1.95 Billion INR | 0.22% |
| 2013 Q2 | 2.1 Billion INR | 7.74% |
| 2013 Q3 | 2.12 Billion INR | 0.68% |
| 2013 FY | 8.15 Billion INR | -1.98% |
| 2013 Q4 | 1.96 Billion INR | -7.36% |
| 2012 Q1 | 2.17 Billion INR | 13.01% |
| 2012 Q2 | 2.11 Billion INR | -2.78% |
| 2012 FY | 8.31 Billion INR | 18.23% |
| 2012 Q4 | 1.95 Billion INR | -5.72% |
| 2012 Q3 | 2.07 Billion INR | -2.17% |
| 2011 Q3 | 1.84 Billion INR | 10.42% |
| 2011 FY | 7.03 Billion INR | 40.65% |
| 2011 Q2 | 1.67 Billion INR | 0.0% |
| 2011 Q4 | 1.92 Billion INR | 4.25% |
| 2010 FY | 5 Billion INR | 42.22% |
| 2009 FY | 3.51 Billion INR | 4.87% |
| 2008 FY | 3.35 Billion INR | 14.13% |
| 2007 FY | 2.93 Billion INR | 61.34% |
| 2006 FY | 1.82 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Biocon Limited | 147.55 Billion INR | 99.555% |
| Blue Jet Healthcare Limited | 7.11 Billion INR | 90.78% |
| Concord Biotech Limited | 9.98 Billion INR | 93.426% |
| Dishman Carbogen Amcis Limited | 26.15 Billion INR | 97.492% |
| Jubilant Ingrevia Limited | 41 Billion INR | 98.4% |
| Lyka Labs Limited | 1.05 Billion INR | 37.595% |
| Panacea Biotec Limited | 5.59 Billion INR | 88.267% |
| Piramal Pharma Limited | 81.71 Billion INR | 99.197% |
| SMS Lifesciences India Limited | 3.05 Billion INR | 78.557% |
| Supriya Lifescience Limited | 5.7 Billion INR | 88.497% |
| Syngene International Limited | 34.88 Billion INR | 98.119% |
| Zota Health Care Limited | 1.8 Billion INR | 63.65% |